Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tartrate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    219 result(s) found for: Tartrate. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-000063-25 Sponsor Protocol Number: AX-CL-09e Start Date*: 2005-06-10
    Sponsor Name:Axonyx Inc
    Full Title: A 26 week double-blind extension to a 26 week randomised, double-blind placebo-controlled study that evaluated the safety and efficacy of two different doses of phenserine-tartrate in patients with...
    Medical condition: Alzheimer's disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain ne...
    Disease: Version SOC Term Classification Code Term Level
    4.1 10001897 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019079-32 Sponsor Protocol Number: 190342-033D Start Date*: 2010-05-19
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
    Medical condition: Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004232-66 Sponsor Protocol Number: AOIFUTIER2011 Start Date*: 2012-01-05
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title:
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000089-11 Sponsor Protocol Number: AX-CL-09 Start Date*: 2004-12-15
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimer's Disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007948-34 Sponsor Protocol Number: ANRS 144 Start Date*: 2009-02-27
    Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales. ANRS.
    Full Title: Essai randomisé en double insu comparant l’efficacité et la tolérance du tartrate de varénicline versus placebo dans l’aide à l’arrêt de la consommation de tabac chez les patients infectes infectés...
    Medical condition: Sevrage tabagique chez les patients VIH+ "tobacco user"
    Disease: Version SOC Term Classification Code Term Level
    11.1 10057581 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001187-52 Sponsor Protocol Number: AX.- CL – 06a Start Date*: 2004-11-12
    Sponsor Name:Axonyx Corporation
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Two Different Dosages of Phenserine-tartrate in Patients with Mild to Moderate Probable Alzheimer’s Disea...
    Medical condition: Alzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking. In addition to the cognitive d...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001896 Prim
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002159-89 Sponsor Protocol Number: NLD-PEG-14-10784 Start Date*: 2015-11-05
    Sponsor Name:Biogen MA
    Full Title: Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a
    Medical condition: Erythema at injection site after Plegridy injection for the treatment of Multiple Sclerose.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001487-37 Sponsor Protocol Number: 190342-032D Start Date*: 2008-11-05
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br...
    Medical condition: Geographic Atrophy from Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015586-31 Sponsor Protocol Number: 190342-031D Start Date*: 2010-01-29
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug ...
    Medical condition: Rhegmatogenous Macula-off Retinal Detachment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065569 Rhegmatogenous retinal detachment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000933-12 Sponsor Protocol Number: AX-CL-10 Start Date*: 2005-02-22
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005540-34 Sponsor Protocol Number: CLR_14_12 Start Date*: 2016-07-19
    Sponsor Name:Sun Pharma Advanced Research Company, Ltd. (SPARC)
    Full Title: A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tar...
    Medical condition: Open-angle glaucoma, chronic angle closure glaucoma with patent iridotomy, pseudoexfoliation, pigment dispersion, or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004105-16 Sponsor Protocol Number: MO29872 Start Date*: 2017-12-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAG...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PT (Completed) PL (Completed) ES (Ongoing) IE (Completed) BE (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000301-37 Sponsor Protocol Number: EFC13738 Start Date*: 2018-10-09
    Sponsor Name:Genzyme Corporation
    Full Title: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3
    Medical condition: Congenital, hereditary and neonatal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10075697 Gaucher's disease type I PT
    20.0 10010331 - Congenital, familial and genetic disorders 10075699 Gaucher's disease type III PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) IT (Trial now transitioned) NL (Ongoing) ES (Ongoing) Outside EU/EEA GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-001336-22 Sponsor Protocol Number: AX-PC-201 Start Date*: 2004-11-03
    Sponsor Name:Axonyx Inc.
    Full Title: Effect of Phenserine Treatment on Amyloid in Brains of Patients with Mild Probable Alzheimer’s Disease as studied by Positron Emission Tomography (PET). A Randomised, three Months Double-Blind, Pla...
    Medical condition: Alzheimer’s Disease (AD) is the most common disease leading to dementia and it affects approximately 4 to 8% of the population aged above 65 years. The disease incidence is closely correlated with ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000963-81 Sponsor Protocol Number: PM0259CA221B0 Start Date*: 2004-11-15
    Sponsor Name:Robapharm AG
    Full Title: A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines
    Medical condition: Treatment in metastatic breast cancer previously treated with anthracyclines
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005686-12 Sponsor Protocol Number: RD.03.SPR.29107 Start Date*: 2013-05-23
    Sponsor Name:Galderma R&D
    Full Title: Patient-reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea
    Medical condition: Erythema of rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002533-18 Sponsor Protocol Number: 4618-008-10 Start Date*: 2012-06-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: 52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022121-15 Sponsor Protocol Number: 4618-008 Start Date*: 2011-04-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) DK (Completed) AT (Completed) NO (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001904-10 Sponsor Protocol Number: PM0259CA301J1 Start Date*: 2004-09-15
    Sponsor Name:Pierre Fabre Médicament represented by IRPF
    Full Title: Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic ...
    Medical condition: Treatment in locally advanced or metastatic non-small-lung cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001607-35 Sponsor Protocol Number: A3051044 Start Date*: 2005-01-26
    Sponsor Name:Pfizer Ltd.
    Full Title: AN OPEN-LABEL, MULTICENTER STUDY WITH FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE IN COMPARISON TO TRANSDERMAL NICOTINE PATCH FOR SMOKING CESSATION
    Medical condition: Partial nicotine agonist for use as an aid to smoking cessation.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10057852 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 07:02:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA